Literature DB >> 29486013

Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts.

Joshua D Wallach1, Joseph S Ross2,3.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29486013     DOI： 10.1001/jama.2017.21897

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  11 in total

1.  Gabapentin Use for Hospitalized Neonates.

Authors:  Hibo H Abdi; Nathalie L Maitre; Kristen L Benninger; Mark E Hester; Jonathan L Slaughter
Journal:  Pediatr Neurol       Date:  2019-02-21       Impact factor: 3.372

2.  Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers.

Authors:  Mance E Buttram; Steven P Kurtz; Matthew S Ellis; Theodore J Cicero
Journal:  J Subst Abuse Treat       Date:  2019-07-21

3.  Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV.

Authors:  Benjamin J Oldfield; Kathleen A McGinnis; E Jennifer Edelman; Emily C Williams; Adam J Gordon; Kathleen Akgün; Stephen Crystal; Lynn E Fiellin; Julie R Gaither; Joseph L Goulet; P Todd Korthuis; Brandon D L Marshall; Amy C Justice; Kendall Bryant; David A Fiellin; Kevin L Kraemer
Journal:  J Subst Abuse Treat       Date:  2019-11-06

4.  Factors Associated with Gabapentin Misuse among People Who Inject Drugs in Appalachian Kentucky.

Authors:  Mance E Buttram; Hilary L Surratt
Journal:  Subst Use Misuse       Date:  2020-09-11       Impact factor: 2.164

5.  A Qualitative Examination of Gabapentin Misuse Inside of Treatment and Recovery Settings.

Authors:  Mance E Buttram; Steven P Kurtz
Journal:  J Stud Alcohol Drugs       Date:  2020-09       Impact factor: 2.582

6.  Association Between Dual Trajectories of Opioid and Gabapentinoid Use and Healthcare Expenditures Among US Medicare Beneficiaries.

Authors:  Lili Zhou; Sandipan Bhattacharjee; C Kent Kwoh; Daniel C Malone; Patrick J Tighe; Gary M Reisfield; Marion Slack; Debbie L Wilson; Wei-Hsuan Lo-Ciganic
Journal:  Value Health       Date:  2021-01-11       Impact factor: 5.725

7.  Patterns and predictors of off-label prescription of psychiatric drugs.

Authors:  Aishwarya Vijay; Jessica E Becker; Joseph S Ross
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

8.  Descriptions of Gabapentin Misuse and Associated Behaviors among a Sample of Opioid (Mis)users in South Florida.

Authors:  Mance E Buttram; Steven P Kurtz
Journal:  J Psychoactive Drugs       Date:  2020-08-04

9.  Trends, Patient and Prescriber Characteristics in Gabapentinoid Use in a Sample of United States Ambulatory Care Visits from 2003 to 2016.

Authors:  Lili Zhou; Sandipan Bhattacharjee; C Kent Kwoh; Patrick J Tighe; Daniel C Malone; Marion Slack; Debbie L Wilson; Joshua D Brown; Wei-Hsuan Lo-Ciganic
Journal:  J Clin Med       Date:  2019-12-29       Impact factor: 4.241

10.  Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.

Authors:  Meera Dhodapkar; Audrey D Zhang; Jeremy Puthumana; Nicholas S Downing; Nilay D Shah; Joseph S Ross
Journal:  JAMA Netw Open       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.